康希诺生物股份公司于2026年3月2日发布截至2026年2月28日的月度股份变动报告。公告显示，公司注册股本为人民币247,043,801元。其中，H股（股票代码：06185.HK）132,670,900股、A股（股票代码：688185.SH）114,372,901股，较上月底均无变化。
报告期内，公司未发生新增发行、购回或注销股份事项，亦无库藏股数量变动。公司已披露的2025年核心管理层H股购股权计划（合计860,000股购股权）与2025年A股限制性股票激励计划（首次授予2,054,600股限制性股票）在本月均无行权、失效或其他变动。
截至2月末，公司股本结构保持稳定。公司声明将继续遵守香港联交所《上市规则》及相关法律法规要求。本次公告由联席公司秘书崔进签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.